source
- Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCCBradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.onclive · 2mo ago↗ source
- Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't wantMadrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…Endpoints · 2mo ago↗ source
- Healthcare organizations are increasingly building their own AI toolsBig healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find…